Teva Pharmaceutical Industries Limited (TEVA) stock prices updated...
 

Teva Pharmaceutical Industries Limited stock price

Teva Pharmaceutical Industries Limited latest news:


  • 11/13/2017 06:04:12

    Teva's stock drops after J.P. Morgan downgrades to rare bearish rating

    Shares of Teva Pharmaceutical Industries Ltd. shed 2.2% in premarket trade Monday, after the generic drug maker was downgraded at J.P. Morgan to a rare bearish rating, citing concerns over the U.S. generics business and growing debt levels. Analyst Chris Schott cut his rating to underweight, after being at neutral the past 10 months. Only 6% of companies covered by J.P. Morgan analysts have an underweight rating. "While admittedly Teva shares have been under pressure (down 68% in 2017 and 16% since 3Q results), we see an extended road to recovery and no clear fundamental inflection in sight given ongoing challenges in the company's U.S. generics business (which we do not see growing until 2019), Copaxone generic competition, and growing levels of leverage (>5x in 2018 based on our estimates). Last week, Fitch Ratings downgraded Teva's credit rating in "junk" territory. Teva's stock has underperformed its peers and the broader market by a wide margin, as the SPDR S&P Pharmaceuticals ETF has gained 5.7% year to date and the S&P 500 has climbed 15%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/07/2017 05:38:39

    Teva's stock, bonds fall after credit rating slashed to junk at Fitch

    Shares of Teva Pharmaceutical Industries Ltd. sank 3.6% in premarket trade Tuesday, after the Israel-based generic drug maker's credit rating was cut by two notches into "junk" territory by Fitch Ratings. Teva's most active bonds, the 3.150% notes that mature in October of 2026, fell about 3 points to 83 cents on the dollar, sending its yield up to 5.466%. The spread widened by 27 basis points to 315 basis points over comparable Treasuries. The credit rating agency said the cut in the rating, down to BB from BBB-, reflects concerns over "significant operational stress" at a time when it needs to reduce debt. "Pricing pressure in Teva's North American generics segment and erosion of sales of Copaxone will continue to weigh on free cash flow in the near term, requiring the company to continue to sell assets or find external capital resources to meed debt obligations in 2018 and 2019 and beyond," Fitch said in a statement. The rating outlook is negative. Teva's stock has plunged 66% year to date through Monday, while the SPDR S&P Pharmaceuticals ETF has gained 5.4% and the S&P 500 has climbed 16%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/04/2017 07:31:39

    U.S. stocks open slightly lower; Dow on track to end 5-day win streak

    U.S. stocks opened with modest losses on Wednesday, with major indexes set to take a pause after a series of record finishes. The Dow Jones Industrial Average slipped 5 points to 22,637. The S&P 500 was down 2 points to 2,533, a drop of 0.1%. The Nasdaq Composite Index was off 9 points, or 0.1%, to 6,523. All three indexes closed at records for a second straight day on Tuesday. In the latest economic data, private-sector employers added 135,000 jobs in September, fewer than had been expected, and down sharply from the 237,000 that had been added in August. Among the day's most actively traded names, Mylan NV jumped 18% after the Food and Drug Administration approved its generic versions for Teva Pharmaceutical Industries Ltd.'s Copaxone, a drug for people with relapsing forms of multiple sclerosis. Shares of Teva dropped 14%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 14:31:12

    Cooper Cos. buys Teva IUD line for $1.1 billion

    Teva Pharmaceuticals Industries Ltd. said late Monday it is selling its Paragard IUD product to Cooper Cos. for $1.1 billion cash. Paraguard had sales of about $168 million for the 12 months ending June 30. The deal includes Teva's plant in Buffalo, N.Y., which makes the Paragard. The deal is expected to close by the end of the year. Teva said it will continue to divest the remaining assets in its women's health business, and in its oncology and pain relief businesses in Europe. Cooper said it expects the deal to add 70 cents to 75 cents a share to earnings in the first year. U.S.-traded Teva shares rose 1.1% to $18.72 after hours, while Cooper shares gained 0.2% to $254. On Monday, Teva shares had their biggest one-day gain since 1984 following the naming of a new chief executive.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 12:50:08

    Drugmaker Teva hires new CEO to restore its health

    Teva Pharmaceutical Industries Ltd names H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Amy Pollock reports Video provided by Reuters        

  • 09/11/2017 11:19:47

    Dow industrials rally 260 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 262 points, or 1.2%, at 22,060, while the S&P 500 index climbed 1.1% at 2,488, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 10:42:41

    Dow industrials rally 250 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 250 points, or 1.2%, at 22,054, while the S&P 500 index climbed 1.1% at 2,487, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 08:08:13

    Dow industrials rally 200 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 201 points, or 0.9%, at 22,010, while the S&P 500 index climbed 0.9% at 2,483, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.2% at 6,438, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 07:46:16

    Dow industrials rally nearly 200 points as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 190 points, or 0.9%, at 21,986, while the S&P 500 index climbed 0.8% at 2,481, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.1% at 6,432, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/08/2017 12:08:06

    Allergan $13.75 mln agreement with Saint Regis Mohawk Tribe a play to protect key dry eye product

    Allergan PLC shares rose 1.8% in heavy Friday afternoon trade on news of an unorthodox agreement the company has made with the Saint Regis Mohawk Tribe that could protect patents on a key Allergan dry eye product, Restasis. Under the agreement, the Saint Regis Mohawk Tribe now owns patents on Restasis -- which are expected to expire at the end of August 2024 -- and has granted Allergan exclusive licenses on the product. The Saint Regis Mohawk Tribe is filing to dismiss patent challenges under the U.S. Patent and Trade Office's inter partes review process "based on their sovereign immunity from IPR challenges," Allergan said, although the agreement does not affect recent patent litigation in a Texas federal court. Teva Pharmaceutical Industries Ltd. , Mylan NV and Akorn Inc. have all filed IPR challenges related to Restasis. Allergan will pay the Saint Regis Mohawk Tribe $13.75 million upfront and $15 million in annual royalties; an Allergan spokesperson said the latter is for commercial rights to Restasis. The Saint Regis Mohawk Tribe and its lawyer approached Allergan about the agreement, according to a Friday Allergan statement, and there is case law precedent of universities using this approach. The Allergan agreement is "part of our overall economic diversification strategy," the Saint Regis Mohawk Tribal Council said in a statement. "We realize that we cannot depend solely on casino revenues and, in order for us to be self-reliant, we must enter into diverse business sectors to address the chronically unmet needs of the Akwesasne community; such as housing, employment, education, healthcare, cultural and language preservation." Allergan shares have lifted 1.2% over the last three months, compared to a 1.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Texas Pacific Land TrustTPL | Textainer Group Holdings LimitedTGH | Textron Inc.TXT | Textura CorporationTXTR | Thai FundTTF | The AES CorporationAES | The AES CorporationAES^C | The Blackstone Group L.P.BX | The Charles Schwab CorporationSCHW | The Charles Schwab CorporationSCHW^B |